Survival benefits of chemotherapy for unresectable biliary tract cancer - A multicenter retrospective analysis

Akihiro Funakoshi; Hikoyuki Horiuchi; Terufumi Sakai; Toshihiko Miyahara; Toru Muranaka; Masashi Nakamura; Kazuhiro Mizumoto; Toshiharu Ueki; Akinobu Taketomi; Hiroya Yamaguchi; Toshihiko Sumii; Tetsuhide Ito

Survival benefits of chemotherapy for unresectable biliary tract cancer - A multicenter retrospective analysis

Akihiro Funakoshi, Hikoyuki Horiuchi, Terufumi Sakai, Toshihiko Miyahara, Toru Muranaka, Masashi Nakamura, Kazuhiro Mizumoto, Toshiharu Ueki, Akinobu Taketomi, Hiroya Yamaguchi, Toshihiko Sumii, Tetsuhide Ito

Research output: Contribution to journal › Article › peer-review

Abstract

There is no agreement on the standard chemotherapeutic regimen for biliary tract cancer (BTC), although multi-drug regimens such as gemcitabine and/or S-1 have been tested in clinical trials. This study retrospectively reviewed data from patients with BTC who were seen at hospitals in the Kitakyushu and Fukuoka areas between 2005 and 2006, and examined the effect of systemic chemotherapy regimen on survival benefits in patients with unresectable BTC. Chemotherapy may benefit patients with BTC any age group, regardless of the primary site.

Original language	English
Pages (from-to)	2875-2879
Number of pages	5
Journal	Japanese Journal of Cancer and Chemotherapy
Volume	37
Issue number	13
Publication status	Published - Dec 2010

All Science Journal Classification (ASJC) codes

Medicine(all)

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Cite this

@article{9451e6fbfa8a4e119e5acfefc93b9348,

title = "Survival benefits of chemotherapy for unresectable biliary tract cancer - A multicenter retrospective analysis",

abstract = "There is no agreement on the standard chemotherapeutic regimen for biliary tract cancer (BTC), although multi-drug regimens such as gemcitabine and/or S-1 have been tested in clinical trials. This study retrospectively reviewed data from patients with BTC who were seen at hospitals in the Kitakyushu and Fukuoka areas between 2005 and 2006, and examined the effect of systemic chemotherapy regimen on survival benefits in patients with unresectable BTC. Chemotherapy may benefit patients with BTC any age group, regardless of the primary site.",

author = "Akihiro Funakoshi and Hikoyuki Horiuchi and Terufumi Sakai and Toshihiko Miyahara and Toru Muranaka and Masashi Nakamura and Kazuhiro Mizumoto and Toshiharu Ueki and Akinobu Taketomi and Hiroya Yamaguchi and Toshihiko Sumii and Tetsuhide Ito",

year = "2010",

month = dec,

language = "English",

volume = "37",

pages = "2875--2879",

journal = "Japanese Journal of Cancer and Chemotherapy",

issn = "0385-0684",

publisher = "Japanese Journal of Cancer and Chemotherapy Publishers Inc.",

number = "13",

}

TY - JOUR

T1 - Survival benefits of chemotherapy for unresectable biliary tract cancer - A multicenter retrospective analysis

AU - Funakoshi, Akihiro

AU - Horiuchi, Hikoyuki

AU - Sakai, Terufumi

AU - Miyahara, Toshihiko

AU - Muranaka, Toru

AU - Nakamura, Masashi

AU - Mizumoto, Kazuhiro

AU - Ueki, Toshiharu

AU - Taketomi, Akinobu

AU - Yamaguchi, Hiroya

AU - Sumii, Toshihiko

AU - Ito, Tetsuhide

PY - 2010/12

Y1 - 2010/12

N2 - There is no agreement on the standard chemotherapeutic regimen for biliary tract cancer (BTC), although multi-drug regimens such as gemcitabine and/or S-1 have been tested in clinical trials. This study retrospectively reviewed data from patients with BTC who were seen at hospitals in the Kitakyushu and Fukuoka areas between 2005 and 2006, and examined the effect of systemic chemotherapy regimen on survival benefits in patients with unresectable BTC. Chemotherapy may benefit patients with BTC any age group, regardless of the primary site.

AB - There is no agreement on the standard chemotherapeutic regimen for biliary tract cancer (BTC), although multi-drug regimens such as gemcitabine and/or S-1 have been tested in clinical trials. This study retrospectively reviewed data from patients with BTC who were seen at hospitals in the Kitakyushu and Fukuoka areas between 2005 and 2006, and examined the effect of systemic chemotherapy regimen on survival benefits in patients with unresectable BTC. Chemotherapy may benefit patients with BTC any age group, regardless of the primary site.

UR - http://www.scopus.com/inward/record.url?scp=79960964692&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79960964692&partnerID=8YFLogxK

M3 - Article

C2 - 21160263

AN - SCOPUS:79960964692

SN - 0385-0684

VL - 37

SP - 2875

EP - 2879

JO - Japanese Journal of Cancer and Chemotherapy

JF - Japanese Journal of Cancer and Chemotherapy

IS - 13

ER -

Survival benefits of chemotherapy for unresectable biliary tract cancer - A multicenter retrospective analysis

Abstract

All Science Journal Classification (ASJC) codes

UN SDGs

Other files and links

Fingerprint

Cite this